Trials / Not Yet Recruiting
Not Yet RecruitingNCT07517250
A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients
Non-interventional Study on the Use of ILARIS® (Canakinumab) Among Familial Mediterranean Fever and Still's Disease Patients Across Europe and Israel
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 160 (estimated)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 1 Year
- Healthy volunteers
- Not accepted
Summary
This study aims to assess and characterize the treatment patterns, and long-term clinical outcomes and demographic characteristics of patients diagnosed with Familial Mediterranean fever (FMF) and Still's disease (including systemic juvenile idiopathic arthritis \[SJIA\] and adult-onset Still's disease \[AOSD\]) that received canakinumab for at least 6 months.
Conditions
- Familial Mediterranean Fever
- Still Disease
- Systemic Juvenile Idiopathic Arthritis
- Adult-Onset Still Disease
Timeline
- Start date
- 2026-04-07
- Primary completion
- 2026-09-21
- Completion
- 2026-09-21
- First posted
- 2026-04-08
- Last updated
- 2026-04-08
Source: ClinicalTrials.gov record NCT07517250. Inclusion in this directory is not an endorsement.